Regeneron Pharmaceuticals, Inc. (REGN): יחס חוב להיוון בספרים

Stable demand for medications creates a foundation for the expansion of Regeneron Pharmaceuticals (REGN), despite logistics risks. Reviewing the debt-to-equity ratio history on GURU.Markets confirms stability, where 0.10 reflects the latest metric value. Market capitalization relies on the sale of biologics for ophthalmology and oncology, while the current strategy focuses on expanding the genetic portfolio to reduce dependence on core products.

Stable revenues from Regeneron Pharmaceuticals (REGN) eczema and blindness treatments allow the company to maintain high financial autonomy, minimizing reliance on external borrowing. Analyzing this debt-to-equity chart, an investor assesses the proportion of liabilities within total capital; a decrease in this ratio confirms balance sheet stability, whereas an excessive minimum may signal an underutilization of leverage for expansion.